AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
66_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Accounting_GER
Policies_NN
Basis_NN
of_PIN
accounting_GER
calculated_VBN [PRIV]
after_IN
charging_VBG
the_DT
gross_JJ
amount_NN
,_,
transactions_NOMZ
,_,
except_PIN
relevant_JJ
foreign_JJ
The_DT
Financial_NN
Statements_NOMZ
are_VPRT [PASS]
prepared_VBN
under_IN
at_PIN
current_JJ
exchange_NN
rates_NN
,_,
of_PIN
any_QUAN
such_JJ
currency_NN
loans_NN
,_,
are_VPRT [PASS]
taken_VBN
to_TO
operating_VBG
profit_NN
._.
the_DT
historical_JJ
cost_NN
convention_NOMZ
,_,
modified_VBN [PASTP]
to_PIN
goodwill_NN
._.
In_PIN
the_DT
consolidated_JJ
Financial_NN
Statements_NOMZ
include_VPRT
the_DT
revaluation_NOMZ
to_PIN
market_NN
value_NN
of_PIN
exchange_NN
differences_NN
arising_VBG [WZPRES]
on_PIN
certain_JJ
current_JJ
asset_NN
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
Intangible_JJ
assets_NN
,_,
including_VBG
patents_NN
acquired_VBN
,_,
consolidation_NOMZ
of_PIN
the_DT
net_JJ
investments_NOMZ
in_PIN
Group_NN
subsidiaries_NN
as_IN
described_VBN
below_PLACE
,_,
in_PIN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
their_TPP3
subsidiaries_NN
,_,
joint_JJ
ventures_NN
and_PHC
associates_NN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
estimated_VBD [PRIV]
useful_JJ
lives_NN
generally_RB
not_XX0
together_RB
with_PIN
those_DEMO
on_PIN
relevant_JJ
foreign_JJ
and_CC
UK_NN
generally_RB
accepted_VBD [PRIV] [THATD]
accounting_GER
exceeding_VBG [WZPRES]
20_CD
years_NN
,_,
in_PIN
line_NN
with_PIN
the_DT
benefits_NN
currency_NN
loans_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
principles_NN
UK_NN
GAAP_NN
._.
If_COND
related_JJ
products_NN
fail_VPRT
,_,
the_DT
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
significant_JJ
differences_NN
to_PIN
US_FPP1
GAAP_NN
these_DEMP
remaining_VBG
unamortised_JJ
amounts_NN
are_VPRT
and_CC
losses_NN
._.
have_VPRT [PEAS]
been_VBN [PASS]
described_VBN
in_PIN
the_DT
US_FPP1
GAAP_NN
immediately_TIME
written_VBD [PUBV]
off_PIN
to_PIN
revenue_NN
expense_NN
._.
The_DT
following_JJ
Finance_NN
costs_NN
and_CC
internally_RB
developed_VBD
Taxation_NOMZ
paragraphs_NN
describe_VPRT
the_DT
main_JJ
accounting_GER
intangible_JJ
assets_NN
are_VPRT [PASS]
not_XX0
capitalized_VBN
._.
All_QUAN
The_DT
charge_NN
for_PIN
taxation_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
policies_NN
under_IN
UK_NN
GAAP_NN
._.
The_DT
accounting_GER
intangible_JJ
assets_NN
are_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
profits_NN
for_PIN
the_DT
year_NN
and_CC
takes_VPRT
into_PIN
account_NN
policies_NN
of_PIN
some_QUAN
overseas_PLACE
subsidiaries_NN
and_ANDC
when_RB
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
taxation_NOMZ
deferred_VBN
because_CAUS
of_PIN
timing_NN
associated_VBN
undertakings_GER
do_VPRT
not_XX0
conform_VB
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
differences_NN
between_PIN
the_DT
treatment_NOMZ
of_PIN
certain_JJ
with_PIN
UK_NN
GAAP_NN
and_CC
,_,
where_RB
appropriate_JJ
,_,
items_NN
for_PIN
taxation_NOMZ
and_CC
for_PIN
accounting_GER
adjustments_NOMZ
are_VPRT [PASS]
made_VBN
on_PIN
consolidation_NOMZ
in_PIN
Post-retirement_NOMZ
benefits_NN
purposes_NN
._.
Full_JJ
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
the_DT
tax_NN
order_NN
to_TO
present_VB
the_DT
Group_NN
Financial_NN
The_NN
pension_NN
costs_NN
relating_VBG [WZPRES]
to_PIN
UK_NN
retirement_NOMZ
effects_NN
of_PIN
these_DEMO
differences_NN
._.
No_SYNE
provision_NN
is_VPRT
Statements_NOMZ
on_PIN
a_DT
consistent_JJ
basis_NN
._.
plans_NN
are_VPRT [PASS]
assessed_VBN
in_PIN
accordance_NN
with_PIN
the_DT
made_VBN
for_PIN
unremitted_JJ
earnings_GER
of_PIN
foreign_JJ
advice_NN
of_PIN
independent_JJ
qualified_JJ
actuaries_NN
._.
subsidiaries_NN
where_RB
there_EX
is_VPRT
no_SYNE
commitment_NOMZ
Critical_JJ
accounting_GER
policies_NN
The_DT
amounts_NN
so_EMPH
determined_JJ
include_VPRT
the_DT
to_TO
remit_VB
such_JJ
earnings_GER
,_,
nor_SYNE
is_VPRT [PASS]
provision_NN
made_VBD
AstraZenecas_NN
management_NOMZ
considers_VPRT [PRIV]
the_DT
regular_JJ
cost_NN
of_PIN
providing_VBG
the_DT
benefits_NN
under_IN
for_PIN
rolled_VBN
over_IN
capital_NN
gains_NN
._.
The_DT
deferred_JJ
tax_NN
following_VBG [WZPRES]
to_TO
be_VB [BEMA]
the_DT
most_EMPH
important_JJ
the_DT
plans_NN
which_WDT [WHOBJ]
it_PIT
is_VPRT [PASS]
intended_VBN [SUAV]
should_NEMD
remain_VB
balances_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
accounting_GER
policies_NN
in_PIN
the_DT
context_NN
of_PIN
the_DT
as_IN
a_DT
level_NN
percentage_NN
of_PIN
current_JJ
and_CC
Groups_NN
operations_NOMZ
._.
expected_JJ
future_JJ
earnings_GER
of_PIN
the_DT
employees_NN
Tangible_JJ
fixed_VBN
assets_NN
covered_VBN
under_IN
the_DT
plans_NN
._.
Variations_NOMZ
from_PIN
the_DT
AstraZenecas_NN
policy_NN
is_VPRT
to_TO
write_VB [PUBV]
off_PIN
the_DT
Turnover_NN
regular_JJ
pension_NN
cost_NN
are_VPRT [PASS]
spread_VBN
on_PIN
a_DT
difference_NN
between_PIN
the_DT
cost_NN
of_PIN
each_QUAN
tangible_JJ
Turnover_NN
excludes_VPRT
intercompany_NN
turnover_NN
systematic_JJ
basis_NN
over_IN
the_DT
estimated_VBN [PRIV]
average_JJ
fixed_JJ
asset_NN
and_CC
its_PIT
residual_JJ
value_NN
evenly_RB
over_IN
and_CC
value_NN
added_VBD [PUBV]
taxes_NN
and_CC
represents_VPRT
net_JJ
remaining_VBG
service_NN
lives_NN
of_PIN
current_JJ
employees_NN
its_PIT
estimated_VBN [PRIV]
remaining_VBG
life_NN
._.
Reviews_NN
are_VPRT [BEMA]
invoice_JJ
value_NN
less_RB
estimated_JJ
rebates_NN
,_,
returns_NN
in_PIN
the_DT
plans_NN
._.
Retirement_NOMZ
plans_NN
of_PIN
non-UK_JJ
made_VBN
periodically_RB
of_PIN
the_DT
estimated_VBN [PRIV]
remaining_VBG
and_CC
settlement_NOMZ
discounts_NN
._.
Revenue_NN
is_VPRT
subsidiaries_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
in_PIN
accordance_NN
lives_NN
of_PIN
individual_JJ
productive_JJ
assets_NN
,_,
taking_VBG
recognized_VBN [PRIV]
at_PIN
the_DT
point_NN
at_PIN
which_WDT [PIRE]
title_NN
passes_VPRT
._.
with_PIN
local_JJ
conditions_NOMZ
and_PHC
practice_NN
._.
With_PIN
account_NN
of_PIN
commercial_JJ
and_PHC
technological_JJ
minor_JJ
exceptions_NOMZ
,_,
these_DEMO
subsidiaries_NN
obsolescence_VPRT
as_RB
well_RB
as_IN
normal_JJ
wear_NN
and_PHC
Research_NN
and_PHC
development_NOMZ
recognize_VPRT [PRIV]
the_DT
expected_VBN [PRIV]
cost_NN
of_PIN
providing_VBG
tear_VB
._.
Under_IN
this_DEMO
policy_NN
it_PIT
becomes_VPRT
Research_NN
and_PHC
development_NOMZ
expenditure_NN
is_VPRT
pensions_NN
on_PIN
a_DT
systematic_JJ
basis_NN
over_IN
the_DT
impracticable_JJ
to_TO
calculate_VB [PRIV] [THATD]
average_JJ
asset_NN
lives_VPRT
charged_VBN
to_TO
profit_VB
in_PIN
the_DT
year_NN
in_PIN
which_WDT [PIRE]
it_PIT
is_VPRT [BEMA]
average_PRED
remaining_VBG
service_NN
lives_NN
of_PIN
employees_NN
exactly_RB
._.
However_CONJ
,_,
the_DT
total_JJ
lives_NN
range_VPRT
from_PIN
incurred_VBN
._.
in_PIN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
approximately_RB
13_CD
to_PIN
50_CD
years_NN
for_PIN
buildings_GER
,_,
independent_JJ
qualified_JJ
actuaries_NN
._.
The_DT
costs_NN
of_PIN
and_CC
three_CD
to_PIN
15_CD
years_NN
for_PIN
plant_NN
and_PHC
Goodwill_NN
and_CC
intangible_JJ
assets_NN
providing_VBG [WZPRES]
post-retirement_JJ
benefits_NN
other_JJ
than_PIN
equipment_NOMZ
._.
All_QUAN
tangible_JJ
fixed_JJ
assets_NN
are_VPRT [BEMA]
On_PIN
the_DT
acquisition_NOMZ
of_PIN
a_DT
business_NOMZ
,_,
fair_JJ
values_NN
pensions_NN
,_,
principally_RB
healthcare_NN
,_,
are_VPRT [PASS]
charged_VBN
reviewed_VBN
for_PIN
impairment_NOMZ
when_RB
there_EX
are_VPRT
are_VPRT [PASS]
attributed_VBN
to_PIN
the_DT
net_JJ
assets_NN
acquired_VBN
._.
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
on_PIN
a_DT
consistent_JJ
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
Goodwill_VB
arises_VPRT
where_RB
the_DT
fair_JJ
value_NN
of_PIN
the_DT
basis_NN
over_IN
the_DT
average_JJ
service_NN
lives_NN
of_PIN
be_VB [BEMA]
recoverable_PRED
._.
consideration_NOMZ
given_VBN [WZPAST]
for_PIN
a_DT
business_NOMZ
exceeds_VPRT
employees_NN
._.
Such_JJ
costs_NN
are_VPRT [PASS]
assessed_VBN
in_PIN
the_DT
fair_JJ
value_NN
of_PIN
such_JJ
net_JJ
assets_NN
._.
Goodwill_NN
accordance_NN
with_PIN
the_DT
advice_NN
of_PIN
independent_JJ
Leases_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
since_OSUB
1998_CD
is_VPRT [PASS]
qualified_VBN
actuaries_NN
._.
AstraZeneca_NN
has_VPRT [PEAS]
adopted_VBN
Assets_NN
held_VBN [PRIV]
under_IN
finance_NN
leases_NN
are_VPRT [PASS]
capitalized_VBN
and_PHC
amortised_VBN
over_IN
its_PIT
estimated_VBN [PRIV]
the_DT
disclosure_NN
requirements_NOMZ
of_PIN
FRS_NN
17_CD
._.
capitalized_JJ
and_CC
included_VBD
in_PIN
tangible_JJ
fixed_VBN
useful_JJ
life_NN
generally_RB
not_XX0
exceeding_VBG
20_CD
years_NN
._.
Each_QUAN
asset_NN
is_VPRT [PASS]
depreciated_VBN
Goodwill_NN
is_VPRT [PASS]
reviewed_VBN
for_PIN
impairment_NOMZ
when_RB
Other_JJ
accounting_GER
policies_NN
over_IN
the_DT
shorter_JJ
of_PIN
the_DT
lease_NN
term_NN
or_CC
its_PIT
useful_JJ
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
Foreign_NN
currencies_NN
life_NN
._.
The_DT
obligations_NOMZ
related_VBN
to_TO
finance_VB
leases_NN
,_,
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
The_DT
Groups_NN
policy_NN
Profit_NN
and_PHC
loss_NN
accounts_NN
in_PIN
foreign_JJ
currencies_NN
net_NN
of_PIN
finance_NN
charges_NN
in_PIN
respect_NN
of_PIN
future_NN
up_IN
to_TO
and_CC
including_VBG
1997_CD
was_VBD
to_TO
eliminate_VB
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
average_JJ
periods_NN
,_,
are_VPRT [PASS]
included_VBN
,_,
as_IN
appropriate_JJ
,_,
goodwill_NN
arising_VBG [WZPRES]
upon_PIN
acquisitions_NOMZ
against_PIN
rates_NN
for_PIN
the_DT
relevant_JJ
accounting_GER
periods_NN
._.
under_IN
creditors_NN
due_JJ
within_PIN [STPR]
,_,
or_CC
creditors_NN
due_JJ
reserves_NN
._.
Such_JJ
goodwill_NN
will_PRMD
remain_VB
Assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
after_RB
,_,
one_CD
year_NN
._.
The_DT
interest_NN
element_NOMZ
of_PIN
the_DT
eliminated_VBN
against_PIN
reserves_NN
until_IN
disposal_NN
or_CC
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
the_DT
rental_JJ
obligation_NOMZ
is_VPRT [PASS]
allocated_VBN
to_TO
accounting_VBG
termination_NOMZ
of_PIN
the_DT
previously_TIME
acquired_VBN
Group_NN
balance_NN
sheet_NN
._.
periods_NN
during_PIN
the_DT
lease_NN
term_NN
to_TO
reflect_VB [PRIV] [THATD]
a_DT
business_NOMZ
including_VBG [WZPRES]
the_DT
planned_VBN
disposal_NN
or_CC
constant_JJ
rate_NN
of_PIN
interest_NN
on_PIN
the_DT
remaining_VBG
termination_NOMZ
when_RB
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
Exchange_NN
gains_NN
and_PHC
losses_NN
on_PIN
short_JJ
term_NN
balance_NN
of_PIN
the_DT
obligation_NOMZ
for_PIN
each_QUAN
accounting_VBG
the_DT
value_NN
of_PIN
the_DT
goodwill_NN
has_VPRT [PEAS]
been_VBN [BEMA]
foreign_JJ
currency_NN
borrowings_GER
and_PHC
deposits_NN
period_NN
._.
Rentals_NN
under_IN
operating_VBG
leases_NN
are_VPRT [SPAU] [PASS]
permanently_RB
impaired_VBN
,_,
when_RB
the_DT
profit_NN
or_CC
are_VPRT [PASS]
included_VBN
within_PIN
net_JJ
interest_NN
payable_JJ
._.
charged_VBN [PASTP]
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
as_IN
loss_NN
on_PIN
disposal_NN
or_CC
termination_NOMZ
will_PRMD
be_VB
Exchange_NN
differences_NN
on_PIN
all_QUAN
other_JJ
incurred_VBN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2003_CD
67_CD
Investments_NOMZ
Stock_NN
valuation_NOMZ
An_DT
associate_NN
is_VPRT [BEMA]
an_DT
undertaking_GER
,_,
not_XX0
being_VBG [BEMA]
a_DT
Stocks_NN
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
the_DT
lower_JJ
of_PIN
cost_NN
or_CC
net_JJ
subsidiary_NN
or_CC
joint_JJ
venture_NN
,_,
in_PIN
which_WDT [PIRE]
realisable_JJ
value_NN
._.
The_DT
first_JJ
in_PIN [STPR]
,_,
first_RB
out_PIN
or_CC
an_DT
AstraZeneca_NN
has_VPRT
a_DT
participating_VBG
interest_NN
and_CC
average_JJ
method_NN
of_PIN
valuation_NOMZ
is_VPRT [PASS]
used_VBN
._.
In_PIN
over_IN
whose_WPS
commercial_JJ
and_PHC
financial_JJ
policy_NN
determining_VBG [SUAV] [PRIV] [WZPRES]
cost_NN
,_,
depreciation_NOMZ
is_VPRT [PASS]
included_VBN
decisions_NN
AstraZeneca_NN
exercises_VPRT
significant_JJ
but_CC
selling_GER
expenses_NN
and_CC
certain_JJ
overhead_JJ
influence_NN
._.
expenses_NN
principally_RB
central_JJ
administration_NOMZ
costs_NN
are_VPRT [PASS]
excluded_VBN
._.
Net_JJ
realisable_JJ
value_NN
is_VPRT [BEMA]
A_DT
joint_JJ
venture_NN
is_VPRT [BEMA]
an_DT
entity_NOMZ
in_PIN
which_WDT [PIRE]
determined_VBD [SUAV] [PRIV]
as_IN
estimated_VBN [PRIV]
selling_GER
price_NN
less_RB
AstraZeneca_JJ
holds_VPRT [PRIV]
an_DT
interest_NN
on_PIN
a_DT
long_JJ
term_NN
costs_NN
of_PIN
disposal_NN
._.
basis_NN
and_ANDC
which_WDT
is_VPRT [SPAU] [BYPA]
jointly_RB
controlled_VBN
by_PIN
AstraZeneca_NN
and_CC
one_CD
or_CC
more_EMPH
other_JJ
Principal_NN
financial_JJ
instruments_NOMZ
venturers_NN
under_IN
a_DT
contractual_JJ
arrangement_NOMZ
._.
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
for_PIN
existing_VBG
transactions_NOMZ
are_VPRT [PASS]
revalued_VBN
to_PIN
year_NN
end_NN
AstraZenecas_NN
share_NN
of_PIN
the_DT
profits_NN
less_RB
losses_NN
spot_NN
rates_NN
and_CC
the_DT
gains_NN
losses_NN
arising_VBG [WZPRES]
are_VPRT [BEMA]
of_PIN
all_QUAN
significant_JJ
joint_JJ
ventures_NN
and_PHC
associates_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
is_VPRT [PASS]
included_VBN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
account_NN
._.
Interest_NN
differentials_NN
are_VPRT [PASS]
amortised_VBN
account_NN
on_PIN
the_DT
equity_NOMZ
accounting_GER
basis_NN
or_CC
,_,
in_PIN
on_PIN
a_DT
straight_JJ
line_NN
basis_NN
over_IN
the_DT
life_NN
of_PIN
the_DT
the_DT
case_NN
of_PIN
joint_JJ
ventures_NN
,_,
the_DT
gross_JJ
equity_NOMZ
contract_NN
._.
The_DT
holding_GER
value_NN
of_PIN
significant_JJ
associates_NN
and_CC
joint_JJ
ventures_NN
in_PIN
The_DT
gains_NN
losses_NN
on_PIN
forward_RB
foreign_JJ
the_DT
Group_NN
balance_NN
sheet_NN
is_VPRT [BYPA]
calculated_VBN [PRIV]
by_PIN
exchange_NN
contracts_NN
and_PHC
currency_NN
option_NOMZ
reference_NN
to_PIN
AstraZenecas_NN
equity_NOMZ
in_PIN
the_DT
net_JJ
contracts_NN
hedging_VBG [WZPRES]
anticipated_JJ
exposures_NN
are_VPRT
assets_NN
of_PIN
such_JJ
associates_NN
and_CC
joint_JJ
ventures_NN
,_,
deferred_VBN
until_IN
the_DT
date_NN
the_DT
underlying_VBG
as_IN
shown_VBN [PRIV]
by_PIN
the_DT
most_EMPH
recent_JJ
accounts_NN
transaction_NOMZ
being_VBG [WZPRES] [PASS]
hedged_VBN
is_VPRT [PASS]
completed_VBN
._.
available_JJ
,_,
adjusted_VBN
where_RB
appropriate_JJ
and_CC
including_VBG
goodwill_NN
on_PIN
acquisitions_NOMZ
made_VBN
Interest_NN
rate_NN
swaps_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
on_PIN
an_DT
since_OSUB
1_CD
January_NN
1998_CD
._.
accruals_NN
basis_NN
._.
Cross-currency_NN
swaps_NN
are_VPRT [PASS]
translated_VBN
at_PIN
year_NN
end_NN
exchange_NN
rates_NN
:_:
Fixed_JJ
asset_NN
investments_NOMZ
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
gains_NN
losses_NN
arising_VBG [WZPRES]
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
and_CC
reviewed_VBN
for_PIN
impairment_NOMZ
if_COND
there_EX
are_VPRT
measurement_NOMZ
of_PIN
the_DT
related_JJ
liabilities_NOMZ
and_PHC
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [PASS]
dealt_VBN
with_PIN
in_PIN
the_DT
Group_NN
profit_NN
and_PHC
loss_NN
recoverable_JJ
._.
account_NN
or_CC
reserves_NN
as_IN
appropriate_JJ
._.
Current_JJ
asset_NN
investments_NOMZ
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
Groups_NN
insurance_NN
company_NN
subsidiaries_NN
,_,
to_PIN
the_DT
extent_NN
that_TOBJ
they_TPP3
are_VPRT [SPAU] [PASS]
actively_RB
matched_VBN
against_PIN
insurance_NN
liabilities_NOMZ
,_,
are_VPRT [PASS]
valued_VBN
at_PIN
market_NN
value_NN
and_CC
unrealised_JJ
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
taken_VBN
directly_RB
to_PIN
reserves_NN
via_PIN
the_DT
statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
._.
Realised_VBN [PRIV]
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
taken_VBN
to_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
Contingent_JJ
liabilities_NOMZ
Through_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
legal_JJ
disputes_NN
the_DT
settlement_NOMZ
of_PIN
which_WDT [PIRE]
may_POMD
involve_VB
cost_NN
to_PIN
the_DT
Group_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
where_RB
an_DT
adverse_JJ
outcome_NN
is_VPRT [BEMA]
probable_PRED
and_CC
associated_VBN
costs_NN
can_POMD
be_VB [PASS]
estimated_VBN [PRIV]
reliably_RB
._.
AstraZeneca_NN
is_VPRT [PASS]
exposed_VBN
to_PIN
environmental_JJ
liabilities_NOMZ
relating_VBG [WZPRES]
to_PIN
its_PIT
past_JJ
operations_NOMZ
,_,
principally_RB
in_PIN
respect_NN
of_PIN
soil_NN
and_PHC
groundwater_NN
remediation_NOMZ
costs_NN
._.
Provisions_NN
for_PIN
these_DEMO
costs_NN
are_VPRT [PASS]
made_VBN
when_RB
there_EX
is_VPRT
a_DT
present_JJ
obligation_NOMZ
,_,
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
expenditure_NN
on_PIN
remedial_JJ
work_NN
will_PRMD
be_VB [PASS]
required_VBN [SUAV]
and_CC
a_DT
reliable_JJ
estimate_NN
can_POMD
be_VB [PASS]
made_VBN
of_PIN
the_DT
cost_NN
._.
